Denmark’s Novo Nordisk expects 27% product sales surge this 12 months but faces price pressure for fat decline drug Wegovy amid Eli Lilly level of competition



Novo Nordisk A/S raised its gain outlook with the drugmaker now delivery five instances a lot more introductory doses of its body weight-loss drug Wegovy in the US than at the conclude of final yr.

More than 25,000 clients are now starting off on the treatment each 7 days in the US, Chief Government Officer Lars Fruergaard Jorgensen explained Thursday. That is up from about 5,000 in December.

Ramping up manufacturing is a important element of Novo’s method as it battles Eli Lilly & Co. for supremacy in the excess weight-loss market. The pharma enterprise is doubling its investment decision in producing ability this calendar year to about $6.4 billion — a determine that does not include the planned $11 billion acquisition of three factories at first owned by agreement maker Catalent Inc.

Demand from customers for the obesity blockbuster and its sister drugs for diabetic issues Ozempic prompted the Danish company to enhance its forecast on Thursday, saying sales could surge as considerably as 27% and functioning earnings by as a lot as 30% this 12 months.

The shares fell 2.3% in early trading in Copenhagen. They have surged about 25% this 12 months and virtually doubled because the get started of 2023.

Wegovy Income

Rate pressure on Wegovy in the US held back again the drug’s revenue development in the initially quarter. Revenue for the drugs far more than doubled to 9.38 billion kroner ($1.35 billion), falling short of analysts’ anticipations. Running financial gain rose 27% to 31.8 billion kroner last quarter, the corporation claimed. Novo stated it is even now the worldwide leader in GLP-1 medicines with a current market share of 55%.

Wegovy and Ozempic’s value has been a stage of competition in the US because a Yale University study in March approximated that Ozempic could be profitably generated for significantly less than $5 a month. The drug’s listing rate is $936, with Wegovy at $1,349. 

In an April 24 letter to Jorgensen, Senator Bernie Sanders claimed the Senate Committee on Wellbeing, Education and learning, Labor and Pensions is investigating the drugs’ costs. 

“Prices have appear down linked to volume, breadth of coverage as well as levels of competition, and that will also get position in the remainder of the 12 months,” Chief Financial Officer Karsten Munk Knudsen explained on a conference phone. 

About 80% of Wegovy individuals in the US with industrial coverage for the drug are spending $25 or significantly less per month, in accordance to Novo.

The drugmaker will carry on to impose some restrictions on entry to the lower doses of Wegovy that are employed as clients slowly ramp up on the drug. 

“We’re not placing a time limit on it,” Negelle Morris, a senior vice president, stated in an job interview. “We do be expecting that need is going to continue to outstrip provide.” 

The idea guiding limiting reduced doses of the drug is to give patients assurance that after they development to the better types — supposed to be taken for extensive intervals of time — they will be ready to continue on treatment method. As of this week, the two best doses of Wegovy are outlined as offered in a Food stuff and Drug Administration database that tracks drug shortages. 

Eli Lilly also lifted its outlook this 7 days and predicted that supply and pricing for Zepbound, its competing drug, will boost this calendar year. The industry for obesity treatments may well soar previously mentioned $80 billion by 2030, in accordance to Bloomberg Intelligence. 



Resource website link

Leave a Reply

Your email address will not be published. Required fields are marked *